Welcome to SciBX
SciBX: Science-Business eXchange is a weekly publication that unites the scientific acumen of Nature Publishing Group with the business intelligence of BioCentury Publications, Inc. to provide timely, concise, and understandable analysis of the scientific content and commercial potential of the most important translational research papers with the potential to transform human therapeutics and diagnostics.
By distilling the flood of life sciences literature down to the 25 key scientific developments each week, and providing in-depth analysis of the most important findings, SciBX provides a unique scientific and commercial perspective on today's breakthrough science.
Now the SciBX platform has NEW UPGRADES to suit the diverse information needs of individual, investor, corporate and institutional readers. Subscribers now can obtain sitewide access via html as well as the convenience of individual delivery via PDF.
- SciBX is now available as a full text html site for institutions keen to provide access via a sitewide license. For librarians serving academic and corporate research institutions, the new html site is integrated with the familiar services provided through www.nature.com and can be viewed without charge for a limited time.
View the full text SciBX html site through www.nature.com. VIEW
- All SciBX articles have been integrated into BioCentury's Business Intelligence Platform via the newly upgraded BioCentury Archives 4.0. Individual subscribers and group accounts who receive the PDF version now can combine the entire BioCentury family of publications to conduct product, competitive and investment analysis.
View SciBX PDFs and the BioCentury Archives 4.0. VIEW
- Free trials of SciBX are available in either format. Please contact Subscriber Services for more information.
Order a Free Trial of SciBX. ORDER
If you're serious about translating science into medicines, then you need SciBX.
Week of 25.06.09
To access this content, select one of the VIEW buttons above.
Analysis
Cover story
Low-Rhes approach to Huntington's
Johns Hopkins researchers may have solved a central mystery of Huntington's disease: why the mutant form of the huntingtin protein occurs throughout the body and yet causes pathology primarily in the brain. The proposed target, Rhes, also looks to be druggable.
Translational Notes
Science for export
Although every major university or institute would like to be located in a biotech hub and keep its discoveries close to home, only a few true hubs exist. For everyone else, the question is whether their research will be taken elsewhere for commercialization. In the long run, the answer is usually yes.
Targets & Mechanisms
Seeing CNV sooner
A multinational research team suggests that noninvasive imaging of CCR3 could help detect incipient wet age-related macular degeneration, making earlier therapeutic intervention possible. The researchers also suggest that CCR3 inhibition could be used to augment treatment with VEGF-A inhibitors.
Proteasome progress
Researchers at Proteolix have found a small molecule that inhibits a subunit of the proteasome involved in immune cell activation. The compound's profile could make it suitable for autoimmune indications, an area previously off-limits to general proteasome inhibitors because of toxicity concerns.
The Distillery
- Antagonizing CCR7 to prevent the spread of ALL
- Inhibiting HIF1α to treat cardiac hypertrophy
- Boosting LEPR activity to prevent obesity and diabetes
- Using rapamycin to increase the efficacy of infectious disease vaccines
- And more ...
- Total synthesis of haouamine A
- A mouse model of spontaneous relapsing-remitting multiple sclerosis
- Magnetic nanoparticle-assisted adenoviral gene transfer
- And more ...
